Investor Presentaiton
Investor presentation
Full year 2018
Slide 88
SaxendaⓇ now launched in 41 countries
SaxendaⓇ value share of anti-obesity
medications in selected countries
Mexico
Germany
100%
Australia
Italy
Belgium
USA
Brazil
UAE
Canada
Denmark
DKK
SaxendaⓇ reported sales for full year 2018¹
Saxenda local currency growth
billion
Spain
4.5
60% Operations
IO Regions
4.0
3.5
80%
60%
3.0
39%
2.5
2.0
40%
1.5
131%
1.0
20%
136% 73%
0.5
104% NA*
0%
0.0
0 4 8
12 16 20 24 28 32 36 40
Months from Launch
44
Total
NAO
IO
AAMEO LATAM Europe J&K
Source: IQVIA Nov 2018
Note: The market for anti-obesity medication varies significantly in size between countries
NAO: North America Operations; IO: International Operations; AAMEO: Africa, Asia, Middle
East & Oceania; LATAM: Latin America; J&K: Japan & Korea
*SaxendaⓇ was launched in South Korea within Region Japan & Korea during 2018, hence
'NA' Not ApplicableView entire presentation